Core Insights - Almirall and Absci Corporation are expanding their AI Drug Discovery collaboration to include a second target for dermatological indications, building on the success of their initial collaboration [1][2][4] - The collaboration leverages Absci's Integrated Drug Creation™ platform and Almirall's dermatology expertise to accelerate the development of innovative therapeutics for chronic skin diseases [2][3] - Absci is eligible for up to approximately $650 million in payments across both programs, in addition to royalties on potential product sales [3] Company Overview - Almirall is a global biopharmaceutical company focused on medical dermatology, founded in 1944 and headquartered in Barcelona, with total revenue of €990 million in 2024 and over 2000 employees globally [5][6] - Absci is a clinical-stage biopharmaceutical company that utilizes generative AI for drug discovery, aiming to create better biologics faster [8][9] Collaboration Details - The initial collaboration, announced in November 2023, successfully delivered AI-designed functional antibody leads against a difficult-to-drug target [2][4] - Absci's generative AI platform is combined with wet lab capabilities to design and validate therapeutic candidates, while Almirall leads the preclinical and clinical development [3][4] - The collaboration aims to accelerate innovation in dermatology by utilizing generative AI for new therapeutic approaches [4]

Core Insights - Almonty has successfully transitioned to NASDAQ, highlighting its strategic importance in the U.S. market and marking a new development phase for the company [2][3] - The company issued 20 million shares, initially aiming to raise $75 million, but due to strong market demand, the target was increased to $90 million, with the offering being oversubscribed multiple times [2] - The issuance price was set at a 21% discount compared to the closing price in Canada, indicating a strategic pricing decision to attract investors [2] Company Overview - Almonty's core asset is the Sangdong tungsten mine in South Korea, and it also operates a tungsten mine in Portugal [2] - The company has secured a 15-year tungsten supply contract with a U.S. defense firm, emphasizing its role in the defense industry where tungsten is critical for manufacturing munitions and weaponry [2] - The funds raised from the NASDAQ listing will be utilized for the construction of a tungsten oxide plant in Sangdong, further enhancing its production capabilities [2]